期刊
EUROPEAN JOURNAL OF HAEMATOLOGY
卷 81, 期 5, 页码 329-343出版社
WILEY
DOI: 10.1111/j.1600-0609.2008.01127.x
关键词
multiple myeloma; management; risk stratification
类别
资金
- Belgian Federation against Cancer
- Association for International Cancer Research
- Fonds voor Wetenschappelijk Onderzoek-Vlaanderen
Multiple myeloma is a plasma cell (PC) malignancy characterized by the accumulation of monoclonal PCs in the bone marrow and the production of large amounts of a monoclonal immunoglobulin or paraprotein. In the past years, new approaches in the diagnosis and treatment were introduced aiming to identify high-risk patients who need proper anti-myeloma treatment. Intensive therapy including autologous hematopoietic stem cell transplantation and the new agents bortezomib, thalidomide, and lenalidomide have improved patients' responses. Further optimalization of the different treatment schedules in well-defined patient groups may prolong their survival. Patient stratification is currently based on patient characteristics, extent of myeloma disease, and associated cytogenetic and laboratory anomalies. More and more gene expression studies are introduced to stratify patients and to individualize therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据